StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp (EW) stock

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.23−0.20 (-0.19%)

Close on Nov 18, 2026Market cap $60.65BP/E 60.5Yield –

Edwards Lifesciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Edwards Lifesciences's free cash flow for the twelve months ending Jun 30, 2026 was $1.43B, up 143.9% year over year. For fiscal 2025 it was $1.34B, up 360.5% from the year before. Over ten years it grew 11.6% a year on average. The highest annual figure on record is $1.41B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.34B+360.5%
FY2024Dec 31, 2024$289.90M-54.9%
FY2023Dec 31, 2023$642.80M-34.0%
FY2022Dec 31, 2022$973.60M-30.8%
FY2021Dec 31, 2021$1.41B+117.3%
FY2020Dec 31, 2020$647.30M-30.3%
FY2019Dec 31, 2019$928.50M+35.0%
FY2018Dec 31, 2018$688.00M-17.4%
FY2017Dec 31, 2017$832.60M+57.6%
FY2016Dec 31, 2016$528.30M+18.2%
FY2015Dec 31, 2015$447.00M-52.4%
FY2014Dec 31, 2014$939.40M+158.3%
FY2013Dec 31, 2013$363.70M+43.7%
FY2012Dec 31, 2012$253.10M+9.3%
FY2011Dec 31, 2011$231.60M+22.2%
FY2010Dec 31, 2010$189.60M+87.2%
FY2009Dec 31, 2009$101.30M-1.3%
FY2008Dec 31, 2008$102.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$585.00M+142.8%
Q1 FY2026Mar 31, 2026-$21.10M-109.4%
Q4 FY2025Dec 31, 2025$353.50M–
Q3 FY2025Sep 30, 2025$516.20M+72.1%
Q2 FY2025Jun 30, 2025$240.90M-15.8%
Q1 FY2025Mar 31, 2025$224.40M–
Q4 FY2024Dec 31, 2024-$177.30M-467.1%
Q3 FY2024Sep 30, 2024$299.90M-15.8%
Q2 FY2024Jun 30, 2024$286.10M–
Q1 FY2024Mar 31, 2024-$118.80M-147.0%
Q4 FY2023Dec 31, 2023$48.30M-77.4%
Q3 FY2023Sep 30, 2023$356.20M+42.5%
Q2 FY2023Jun 30, 2023-$14.30M-104.9%
Q1 FY2023Mar 31, 2023$252.60M+14.5%
Q4 FY2022Dec 31, 2022$213.90M-24.6%
Q3 FY2022Sep 30, 2022$250.00M-46.9%
Q2 FY2022Jun 30, 2022$289.10M-36.7%
Q1 FY2022Mar 31, 2022$220.60M+13.4%
Q4 FY2021Dec 31, 2021$283.80M-1.0%
Q3 FY2021Sep 30, 2021$471.20M+317.7%
Q2 FY2021Jun 30, 2021$456.80M+271.4%
Q1 FY2021Mar 31, 2021$194.50M+55.7%
Q4 FY2020Dec 31, 2020$286.60M-13.5%
Q3 FY2020Sep 30, 2020$112.80M-68.8%
Q2 FY2020Jun 30, 2020$123.00M-55.5%
Q1 FY2020Mar 31, 2020$124.90M–
Q4 FY2019Dec 31, 2019$331.40M+40.8%
Q3 FY2019Sep 30, 2019$361.20M+40.4%
Q2 FY2019Jun 30, 2019$276.60M+216.5%
Q1 FY2019Mar 31, 2019-$40.70M-137.7%
Q4 FY2018Dec 31, 2018$235.30M-24.6%
Q3 FY2018Sep 30, 2018$257.20M-4.2%
Q2 FY2018Jun 30, 2018$87.40M-37.4%
Q1 FY2018Mar 31, 2018$108.10M-3.8%
Q4 FY2017Dec 31, 2017$312.00M+126.3%
Q3 FY2017Sep 30, 2017$268.50M+70.2%
Q2 FY2017Jun 30, 2017$139.70M–
Q1 FY2017Mar 31, 2017$112.40M–
Q4 FY2016Dec 31, 2016$137.90M–
Q3 FY2016Sep 30, 2016$157.80M–

More Edwards Lifesciences figures

See a number that looks wrong?